At a glance
ClinicalIndex Comparison RecordN/ACompleted· 187 enrolled
Drug / intervention
Relivion active +1 moredevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The RIME Study - Combined Occipital and Supraorbital Transcutaneous Nerve Stimulation for Treatment of Migraine
In Brief
A clinical study evaluating Relivion active and Relivion Sham for Acute Migraine. Completed, enrolled 187 participants across 12 sites in 2 countries.
Detailed Summary
this study will evaluate the clinical performance and safety of a self administered abortive treatment for migraine headache using combined occipital and supraorbital transcutaneous nerve stimulator (Neurolief device, Relivion®)
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAcute Migraine
CountriesIsrael, United States
Collaborators--
Timeline
N/ACompletedFinished
20192020202120222023202420252026
First PostedAug 2018
Enrollment StartNov 2018
Primary CompletionAug 2020
TodayJul 2026
First PostedAug 15, 2018
Enrollment StartNov 29, 2018
Primary CompletionAug 4, 2020
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 7.9 years ago
Interventions
Relivion activedevice
1 hour self-administered occipital and supraorbital transcutaneous nerve stimulation
Relivion Shamdevice
1 hour self-administered Sham occipital and supraorbital transcutaneous nerve stimulation